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Abstract
Introduction: The aim of the present study was to evaluate technetium-99m sestamibi single photon emission tomography 
(SPECT) myocardial perfusion imaging (MPI) and its association with some clinical and laboratory parameters in an 
asymptomatic systemic lupus erythematosus (SLE) population. 
Materials and Methods: Twenty-one subjects with SLE and no suspected or documented coronary artery disease (CAD) 
accomplished myocardial perfusion imaging. Some SLE and CAD parameters were also evaluated in association with 
myocardial SPECT. 
Results: Twenty-one women with a diagnosis of SLE (mean age 36.9 ± 12.8) entered the study. All patients were in the 
low-risk category for CAD pretest; however, abnormal myocardial perfusion results were found in eight (38%) patients. 
Amongst the traditional CAD risk factors, there was a significant association between the presence of dyslipidemia and 
myocardial perfusion abnormalities (P= 0.047). However, we found no significant association between other traditional 
and SLE-specific risk factors. 
Conclusion:  This study’s significant finding was that asymptomatic CAD is common in SLE patients, even in those thought 
to be low risk for CAD and in the absence of cardiac symptoms.
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Introduction
Atherosclerosis develops more frequently in patients 
with systemic lupus erythematosus (SLE) compared to 
the general population. Premature atherosclerosis is, 
indeed, one of the main causes of mortality in patients 
with SLE1. However, the etiology and pathophysiology of 
premature atherosclerosis has not yet been well defined2. 
In these patients, in addition to the traditional risk fac-
tors of coronary artery disease (CAD), other factors 
come into play3; for example, inflammatory, immuno-
logical, metabolic, and hemostatic factors have been 
identified as independent risk factors for CAD in patients 
with SLE2-5.
Although it has been reported that CAD is clinically 
identifiable among 6.1%–8.9% of adults with SLE6, the 
occurrence of subclinical CAD is more frequent6-8. Thus, 
it is important to develop non-invasive techniques able 
1  Department of Nuclear Medicine, Taleghani Hospital, Shaheed Beheshti 
University of Medical Sciences, Tehran, Iran
2  Department of Rheumatology, Taleghani Hospital, Shaheed Beheshti 
University of Medical Sciences, Tehran, Iran
3 Parsteb Pajouheshyar Medical Sciences Research Institute, Tehran, Iran
4  Golestan Research Center of Gastroenterology and Hepatology (GRCGH), 
Golestan University of Medical Sciences (GUOMS), Gorgan, Iran
5  Bushehr Research Center for Nuclear Medicine, The Persian Gulf 




Bushehr Research Center for Nuclear Medicine, 
The Persian Gulf Biomedical Sciences Institute, 
Boostan 19 Alley, 
Imam Khomeini Street, 
Bushehr, Iran
E-mail: assadipoya@yahoo.com, asadi@bpums.ac.ir
152  Perfusion 26(2)
to detect the early stages of CAD6; this may help SLE 
patients to obtain improved risk factor management9. 
Several studies have investigated the role of myocar-
dial perfusion scans or angiography in patients with 
SLE4,6,10. Also, the association of some CAD risk factors 
with abnormal 99m TC SPECT test results has been 
highlighted in a few studies3. This study aimed to investi-
gate the association of abnormal 99m TC SPECT results 
with a wide spectrum of CAD risk factors, including tra-
ditional risk factors and some SLE-specific risk factors, 
in patients who are asymptomatic for cardiac disease. We 
also evaluated the role of some quantitative measures, 
such as transient ischemic dilation (TID) in this study. 
Methods and Materials
Participants and study design
After approval by the ethical committee of human 
research of Shaheed Beheshti University of Medical 
Sciences, this study was conducted at Taleghani Hospital 
from November 2007 to August 2008. Known cases of 
SLE (based on the American College of Rheumatology 
criteria) who were under treatment for their underlying 
disease were enrolled into the study after obtaining writ-
ten informed consent. Other inclusion criteria included 
gender (female), age (18 to 55 years), normal serum 
homocysteine level, diagnosis of SLE, and receiving 
treatment with glucocorticoids for at least the previous 
twelve months. Patients with specific and non-specific 
complaints of ischemic heart disease (IHD) were 
excluded; for example, those with typical or atypical 
chest pain, previous history of myocardial infarction 
(MI), previous history of coronary interventions (cathe-
terization, coronary artery bypass graft (CABG) and per-
cutaneous transluminal coronary angioplasty (PTCA)), 
presence of congestive heart failure, peripheral arterial 
disease, dipyridamole contraindication and malignancy. 
Pregnant patients and those currently breast feeding 
were also excluded from the study. 
A questionnaire was completed for each patient to 
collect information as follows: demographics, course of 
the underlying disease (SLE), signs and symptoms of dis-
ease activity according to the Systemic Lupus 
Erythematosus Disease Activity Index (SLEDAI), any 
signs or symptoms of heart disease, physical examina-
tion findings, drug history, laboratory data (fasting blood 
sugar (FBS), serum level of triglycerides (TG) and cho-
lesterol, urine analysis, complete blood count, C reactive 
protein (CRP), anti dsDNA, anti cardiolipin and serum 
level of complements). The risk factors for CAD were 
evaluated; these included: (1) Hypertension (systolic 
blood pressure ≥ 140 mmHg or diastolic blood pressure 
≥ 90 mmHg or receiving antihypertensive drugs);
(2) FBS ≥ 126 mg/dl or receiving hypoglycemic agents; 
(3) Dyslipidemia (LDL>130 mg/dl or HDL<35 mg/dl
or TG≥ 200 mg/dl); (4) Smoking; (5) Positive familial 
history (MI or sudden death (before the age of 55 for 
males and 65 for females) among first relatives); (6) Body 
mass index ≥ 30 kg/m2. In addition, the pretest likeli-
hood of CAD was estimated by means of nomograms 
that correlated the presence of diabetes with age, the 
ratio of cholesterol to HDL, gender and smoking11. 
Dipyridamole technetium 99m-sestamibi SPECT 
protocol
All patients were asked to refrain from smoking and con-
suming alcohol or caffeine products for 24 hours before 
the perfusion scan took place3. Also, from 48 hours 
before the perfusion scan, certain medications, including 
β blockers, calcium channel blockers and agents contain-
ing methylxanthine, such as theophylline, aminophylline 
and pentoxyphylline, were stopped. 
A two-phase (dipyridamole-induced stress and rest) 
one-day protocol myocardial perfusion scan was per-
formed utilizing SPECT with 99m TC (MIBI TCK-IR-1200, 
Atomic Energy Organization of Iran, Tehran, Iran). 
The pharmacological stress phase was induced using 
an intravenous slow infusion of 0.56 mg/kg dipyrida-
mole for a period of four minutes, then a bolus of 555 
MBq (15 mCi) of 99m TC was given four minutes after 
the infusion. Twelve-lead electrocardiography (ECG) 
was performed and patients were monitored for blood 
pressure, heart rate and dipyridamole-related complica-
tions before, during and after the test. Three to four 
hours later, 925 MBq (25 mCi )99m TC was injected and 
the rest of the images were taken.
The test was stopped if signs or symptoms such as sec-
ond- or third-degree atrioventricular blockage, systolic 
hypotension (≤ 80 mm Hg), ST segment depression ≥ 2 
mm or angina were observed. Intravenous infusion of 
50–200mg aminophylline was given for one minute if 
cardiac symptoms developed. 
Acquisition and processing protocols
To capture the SPECT images, a large field-of-view sin-
gle-headed gamma camera (ADAC, Genesys, Malpitas, 
CA, USA) equipped with a low-energy, all-purpose, par-
allel-hole collimator was used. Data were obtained from 
64 projections of 25 s each in the 140 KeV photopeak 
over an 180˚ arc in a 64×64 matrix. An expert nuclear 
medicine specialist used the cine display of the rotating 
planar projections to evaluate sub-diaphragmatic activi-
ties, attenuations, and patient motion in order to opti-
mize the quality of the images. A short axis, vertical long 
axis and horizontal long axis were reconstructed from 
the raw data by filtered backprojection with a Butterworth 
filter (ADAC, Genesys), with a cut-off frequency of 0.66 
and an order of five. Images were observed and analyzed 
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by two experienced nuclear medicine physicians who 
were blinded with respect to the study. 
Visual and semi-quantitative SPECT analysis
For assessment, scans were divided into 20 segments, 
congruent with the location of the territories of the vari-
ous coronary arteries. A four-grade scale was used to eval-
uate the segments: normal perfusion, reversible defect 
(RD), reverse reperfusion (RR) and persistent defect 
(PD). RD was considered as the presence of a region with 
decreased or absent myocardial activity on exercise scans, 
which appeared improved on the rest-stage images. RR 
was considered to show reduced perfusion at rest, but 
normal in stress conditions. PD was defined as a region of 
decreased or absent myocardial activity for both exercise 
and rest sets. In addition, transient ischemic left ventricu-
lar dilation (TID) was also measured and a TID ≥ 1.1 
value was considered abnormal12,13.
Statistical analysis
Continuous variables are expressed as the mean ± SD, and 
categorical variables as the absolute values and percent-
ages. Fisher’s exact test and the Mann-Whitney U test 
were used, respectively, for analysis of qualitative and 
quantitative variables. A P-value<0.05 was considered 
statistically significant. Statistical analysis was performed 
utilizing SPSS (SPSS Inc., Chicago, IL, version 15).
Results
Twenty-one women with a diagnosis of SLE and with a 
mean age 36.9 ± 12.8 (ranging from 19 to 54) entered the 
study. According to vessels territories, 3 patients had per-
fusion defects in the LAD (left anterior descending 
artery) extent; 2 subjects in the RCA (right coronary 
artery); 2 subjects in the LCX (left circumflex artery) and 
1 patient in both the LAD and RCA extents. The mean 
perfusion defect was 4.0 ± 2.26%. There was no statisti-
cally significant difference between the ages of cases with 
normal or abnormal MPI (33.61 ± 12.43 years, 42.37 ± 
12.38 years, respectively). The mean of TID was succes-
sively 1.12 ± 0.13 (ranging from 0.87 to 1.42). Abnormal 
myocardial perfusion was found in eight (38%) cases of 
whom 9.5% had fixed defects (Table 1). 
All patients were in the low-risk category for CAD 
pretest. The existence of traditional CAD risk factors 
among the subjects is shown in Table 2. As the table 
shows, there was, however, significant association 
between the presence of dyslipidemia and abnormal 
findings in myocardial perfusion scans (P= 0.047). 
Our results did not show any significant association 
between duration of SLE, duration of corticosteroid con-
sumption, degree of SLE activity and abnormal myocar-
dial perfusion scan results (Table 3). This also applied to 
SLE-related laboratory findings where our results failed 
to show significant differences between patients with 
abnormal myocardial perfusion scans and others (Table 
4). Further analysis did not reveal any significant associa-
tion between TID and all above-mentioned variables.
Table 1. The pattern of abnormal myocardial perfusion scan 
findings
Abnormal myocardial perfusion scan findings Number (%)
PD  2 (9.5)
RD  6 (28.5)
RR  1 (4.7)
TID ≥ 1.1 14 (66.6)
PD, persistent defect; RD, reversible defect; RR, reverse reperfusion; 
TID, transient ischemic dilation.
Table 2. The frequency of CAD risk factors in patients with normal and abnormal myocardial perfusion scan. (In our series, there 
was no obese patient (body mass index ≥ 30 kg/m2))






P value† OR 95% CI
DM 0 (0.0) 1 (12.5) 0.38 – –
HTN 1 (7.6) 2 (25.0) 0.53  4.00 0.30 to 53.47
Dyslipidemia 1 (7.6) 4 (50.0) 0.04 12.00 1.02 to 141.3
Post menopause 1 (7.6) 2 (25.0) 0.53  4.00 0.30 to 53.47
Smoking 0 (0.0) 1 (12.5) 0.38 – –
CAD family history 1 (7.6) 2 (25.0) 0.53  4.00 0.30 to 53.47
High level of CRP 1 (7.6) 0 (0.0) 0.99 – –
BMI(mean ±SD) 24.52 ± 2.69 24.78 ± 1.95 0.85 – –
DM, Diabetes Mellitus; HTN, hypertension; CAD, coronary artery disease; CRP, C reactive protein; OR, odds ratio; CI, confidence interval; 
SD, standard deviation, † Fisher’s exact test.
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Discussion
In the present study, in addition to considering tradi-
tional CAD risk factors, we focused on looking for an 
association between certain SLE-related laboratory find-
ings and myocardial perfusion abnormalities. We set out 
to investigate the relationship of semi-quantitative mea-
sures such as TID to other CAD risk factors in SLE 
patients. The role of 99mTC SPECT testing in patients 
with SLE has been previously described and Czuszynska 
et al.12 suggested that the presence of CAD risk factors in 
women with SLE indicates the usefulness of a perfusion 
scan; however, whether all asymptomatic SLE patients 
should be screened for CAD and whether MPI should be 
the first-line test remains a matter of debate. 
In our series, we found an abnormal myocardial per-
fusion scan in 38% of cases, a result which is consistent 
with previous reports9,13. In 1984, Hosenpud et al.13 eval-
uated 26 patients with SLE, utilizing thallium-201 car-
diac scintigraphy. They found segmental abnormality 
in perfusion scans in 10 cases (38.5%) and concluded 
that these abnormalities are common in SLE patients. 
Similarly, Bruce et al.9 showed that myocardial perfusion 
scan abnormalities may be found in 40% of all women 
with SLE and 35% of women with SLE without a his-
tory of CAD. This percentage is higher in patients with 
non-specific chest complaints and Sun et al.6 showed 
that there was an abnormal myocardial perfusion scan in 
27 cases out of 33 studied subjects (82%).
In addition, 66.6% of our SLE cases also had TID, indi-
cating more regions of myocardium at risk and multivessel 
involvement14. Evidence of TID from myocardial per-
fusion imaging has become a generally well-established 
marker of severe and extensive myocardial ischemia14.
In a recent follow-up study, 37.7% of 122 women 
with SLE had an abnormal MPI and also the MPI was 
strongly and independently predictive of CAD15. There 
was a marked difference in mean age between patients 
with normal and abnormal MPI in that study and our 
study15; the mean age of our participants was about 15 
years younger and this would account for the prevalence 
of higher occult CAD in the earlier study group.
In the published data, the sensitivity of MPI was in a 
range of 85% - 95%, but specificity was lower (80% - 
90%)16-21. The low specificity or presence of false positive 
cases may be due to motion artifacts22, attenuation arti-
facts such as diaphragmatic23 and breast attenuation24 in 
SPECT imaging. In addition, mitral valve prolapse, left 
ventricular hypertrophy and non-ischemic cardiomyopa-
thy can cause false positive results25. However, careful 
attention during acquisition can decrease these numbers. 
The importunity of myocardial perfusion defects in 
patients with SLE is a potential challenge. Schillaci 
et al.8 and Lagana et al.26 showed that, in patients with 
SLE and abnormal myocardial perfusion SPECT results, 
none showed signs of epicardial coronary artery stenosis 
on angiography. Although the current study cannot 
determine the significance of defects showing on MPI 
due to its cross-sectionality in type and because angiog-
raphy was not carried out, the presence of 9.5% of fixed 
defects in the cases may be a powerful indicator of the 
presence of CAD and could also point to atherosclerotic 
disease rather than simple endothelial dysfunction. 
In addition, even in the patients with abnormal MPI, 
but normal angiography, the careful evaluation about 
cardiovascular disease in these subgroup of patients may 
Table 3. The association of duration of SLE, duration of 
corticosteroid consumption and degree of SLE severity with 










Duration of SLE (Years) 5 6 0.25
Duration of corticosteroid 
consumption (Years)
2 4 0.17
Degree of SLE 4 4 0.50
SLE, systemic lupus erythematosus
† Mann-Whitney Test
Table 4. Association of SLE-related laboratory measures with myocardial perfusion scan.  






P value† OR 95% CI
aCL 2 (15.3) 4 (50.0) 0.15 5.50 0.71 to 42.60
Low complement level 1 (7.6) 3 (37.5) 0.26 7.20 0.60 to 87.02
ANA 1 (7.6) 2 (25.0) 0.53 4.00 0.30 to 53.47
Anti dsDNA 2 (15.3) 5 (62.5) 0.06 9.166 1.15 to 73.24
Proteinuria 2 (15.3) 3 (37.5) 0.33 3.30 0.41 to 26.37
Abnormal CBC 0 (0.0) 1 (12.5) 0.38 – –
aCL, anti cardiolipin; ANA, antinuclear antibody; CBC, complete blood count; OR, odds ratio; CI, confidence interval.
† Fisher’s exact test.
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be helpful. In the literature, a number of investigations 
focused on this issue27-36. Alqaisi et al. compared the out-
comes in 125 patients with abnormal MPI and insignifi-
cant CAD with 136 patients as a control group over a 
24-month follow-up. They observed approximately 13% 
of the major adverse cardiac events in the target group 
and 4.2% in the control group ( P=0.022)27. Recently, 
Delcour et al, assessed 48 patients who had ischemia on 
MPI and normal coronary angiography with a mean 7.4 
years follow-up in which 15 subjects (31%) had cardio-
vascular events. They suggested that an abnormal MPI is 
a predictor of a higher prevalence of coronary and 
peripheral vascular events than suggested by a normal 
coronary angiogram28. However, follow-up studies in 
these patients are needed.
The assessment of myocardial ischemia following treat-
ment of patients with coronary artery disease is an impor-
tant point to proper management, which is well recognized 
by MPI37. Shaw et al. also demonstrated that, regardless of 
treatment assignment, the magnitude of residual ischemia 
on follow-up MPI was proportional to the risk for major 
cardiac event, and a 5% decrease in ischemia was asso-
ciated with a remarkable decline in risk37. However, fur-
ther well-designed investigations to evaluate therapeutic 
approaches in these groups may be useful. 
Our results revealed that, in addition to traditional 
risk factors for CAD, an abnormal myocardial perfusion 
scan does have a significant association with dyslipi-
demia. This association has been reported previously3. 
Sella et al.3 assessed the relationship between myocar-
dial perfusion scintigraphy and CAD risk factors in SLE 
and found a significant association between lower HDL 
cholesterol levels and abnormal scintigraphy findings. 
The relationship of serum cholesterol level with subclin-
ical atherosclerosis in the carotid artery in SLE patients 
also has been confirmed in a study conducted by Doria 
and associates38. 
In the present study, we failed to show an association 
between diabetes mellitus and abnormal myocardial per-
fusion scan results — a finding that contradicts a previ-
ous report3. Our different finding may be related to the 
low frequency of diabetics in our sample (n=1). Sun and 
associates6 showed that abnormal findings in myocardial 
perfusion scans of SLE patients are not related to DM, 
CAD family history, smoking or being post-menopausal. 
We also failed to show an association between any of 
these factors and abnormal perfusion scan results. 
However, in other studies that evaluated atherosclerosis 
in the carotid artery, an association between traditional 
CAD risk factors and subclinical atherosclerosis in the 
carotid artery in SLE patients has been reported38,39. 
Older age at diagnosis of SLE and duration of taking 
corticosteroids have been suggested as CAD risk factors 
in patients with SLE40-43. However, we failed to show 
significant association between the duration of SLE or 
corticosteroid consumption and myocardial perfusion 
abnormalities. The role of corticosteroids in the patho-
genesis of atherosclerosis is controversial41,42,44. Doria
et al.38 showed a significant association between cumu-
lative doses of prednisone as well as duration of treat-
ment and carotid artery plaque. 
An association of antiphospholipid antibodies and 
atherosclerosis or myocardial infarction in patients with 
SLE has been reported45,46 and the role of these antibod-
ies in the development of arterial and venous thrombosis 
has been well defined47. Doria et al.38 in their study failed 
to find a significant association between anticardiolipin 
antibodies (aCL) and the presence of carotid plaque in 
patients with SLE. In this study, we also did not find an 
association between aCL and abnormal myocardial per-
fusion scan results. 
It should be mentioned that our study had some draw-
backs. One of the most important limitations is the rela-
tively small sample size and it is possible that the study 
lacked the robustness needed to fully identify an associa-
tion between risk factors and myocardial perfusion 
scans. Other limitation, we did not perform attenuation 
correction, which may influence on inferior cardiac wall 
interpretation; however, due to careful examination of 
cine displays to evaluate sub-diaphragmatic activities, 
attenuations, and patient motion in order to optimize the 
quality of the images in our non-obese participants, we 
expected to minimize this problem . 
Furthermore, the kind of current cross-sectional study 
is another important limitation. Some patients had abnor-
mal MPI results which prolong time course monitoring 
which, in future studies, should be taken into account.
Conclusion
This study emphasizes that asymptomatic CAD in SLE 
patients is common, even in the low-risk category and 
even with the absence of cardiac symptoms. Our results 
might indicate the value of performing 99m TC SPECT 
as a non-invasive imaging modality for this category of 
SLE patients. However, performing more evidence-based 
studies with larger samples is strongly recommended.
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